Surgical treatment of medullary thyroid carcinoma

被引:64
作者
Cohen, MS [1 ]
Moley, JF [1 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, Sect Endocrine & Oncol Surg, St Louis, MO 63110 USA
关键词
medullary thyroid carcinoma; multiple endocrine neoplasia; RET proto-oncogene; neck dissection; diagnostic laparoscopy; neck reoperation;
D O I
10.1046/j.1365-2796.2003.01166.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Medullary thyroid carcinoma (MTC) is a malignancy of the parafollicular C cells of the thyroid gland. It occurs sporadically or as part of the multiple endocrine neoplasia type 2 (MEN 2) syndromes. Patients who have inherited a mutation in the RET proto-oncogene should have thyroidectomy early in life to prevent formation and spread of this cancer. Most patients with sporadic disease present with a palpable neck mass. The diagnosis is made by fine needle aspiration biopsy and by measuring calcitonin levels in the blood. Primary treatment consists of surgical resection including a total thyroidectomy, central neck nodal dissection and functional lateral neck nodal dissections. Most patients with a palpable primary tumour have nodal disease present at the time of operation, and nodal involvement is often bilateral. Adequate resection of the primary tumour and cervical lymph nodes is important to optimize outcome and minimize the risk of recurrent disease. Proper handling of the parathyroid glands prevents hypoparathyroidism. Following primary surgical resection, more than half of the patients will have recurrent disease with persistent elevation of calcitonin levels. Currently, there is no adequate systemic therapy for treating recurrent disease. Surgical reoperation or conservative observation are the best available options. Diagnostic laparoscopy for liver evaluation is the most sensitive diagnostic test to detect the presence of distant metastases.
引用
收藏
页码:616 / 626
页数:11
相关论文
共 54 条
[1]  
BERGHOLM U, 1989, CANCER, V63, P1196, DOI 10.1002/1097-0142(19890315)63:6<1196::AID-CNCR2820630626>3.0.CO
[2]  
2-O
[3]   A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A [J].
Berndt, I ;
Reuter, M ;
Saller, B ;
Frank-Raue, K ;
Groth, P ;
Grussendorf, M ;
Raue, F ;
Ritter, MM ;
Höppner, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :770-774
[4]  
BLOCK MA, 1980, ARCH SURG-CHICAGO, V115, P142
[5]   Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control [J].
Brierley, J ;
Tsang, R ;
Simpson, WJ ;
Gospodarowicz, M ;
Sutcliffe, S ;
Panzarella, T .
THYROID, 1996, 6 (04) :305-310
[6]  
BUHR HJ, 1993, CANCER, V72, P3685, DOI 10.1002/1097-0142(19931215)72:12<3685::AID-CNCR2820721221>3.0.CO
[7]  
2-3
[8]   Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene [J].
Ceccherini, I ;
Pasini, B ;
Pacini, F ;
Gullo, M ;
Bongarzone, I ;
Romei, C ;
Santamasia, G ;
Matera, I ;
Mondellini, P ;
Scopsi, L ;
Pinchera, A ;
Pierotti, MA ;
Romeo, G .
ONCOGENE, 1997, 14 (21) :2609-2612
[9]  
CHONG GC, 1975, CANCER, V35, P695, DOI 10.1002/1097-0142(197503)35:3<695::AID-CNCR2820350323>3.0.CO
[10]  
2-W